HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Review Of Children’s Cough/Cold OTCs Has Broader Implications

This article was originally published in The Tan Sheet

Executive Summary

FDA's review of children's over-the-counter cough/cold products will address the broader issue of whether extrapolating pediatric doses from adult dosing data is appropriate

You may also be interested in...



House Appropriators Push For Revised Pediatric Cough/Cold Labels

House appropriators want FDA to propose by Dec. 31 revised labeling for OTC pediatric cough and cold products that addresses safety and efficacy concerns.

Industry Must Adapt To Emerging Trends That Threaten Recent Economic Gain

The OTC industry must adapt to evolving market trends as the global economy recovers in order to maintain the market share it gained during the recession, said experts at a European industry conference

FDA Chief Counsel Has History With Sharfstein

FDA named Ralph Tyler, currently Maryland's insurance commissioner, as the agency's new chief counsel

Related Content

Topics

UsernamePublicRestriction

Register

RS137874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel